Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Lack of tyramine pressor response effect with oral CX157: A specific reversible MAOI.

Burch D, Asgharnejad M, Gerson W, Fielding RM, Azzaro AJ.

Clin Pharmacol Drug Dev. 2014 Jan;3(1):4-12. doi: 10.1002/cpdd.61. Epub 2013 Oct 22.

PMID:
27128224
2.

Phase I study of GRN1005 in recurrent malignant glioma.

Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY.

Clin Cancer Res. 2013 Mar 15;19(6):1567-76. doi: 10.1158/1078-0432.CCR-12-2481. Epub 2013 Jan 24.

3.

Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.

Fowler JS, Logan J, Azzaro AJ, Fielding RM, Zhu W, Poshusta AK, Burch D, Brand B, Free J, Asgharnejad M, Wang GJ, Telang F, Hubbard B, Jayne M, King P, Carter P, Carter S, Xu Y, Shea C, Muench L, Alexoff D, Shumay E, Schueller M, Warner D, Apelskog-Torres K.

Neuropsychopharmacology. 2010 Feb;35(3):623-31. doi: 10.1038/npp.2009.167. Epub 2009 Nov 4.

4.

Pharmacokinetic study of Noni fruit extract.

Issell BF, Franke A, Fielding RM.

J Diet Suppl. 2008;5(4):373-82. doi: 10.1080/19390210802519671.

PMID:
22436097
5.

2-hydroxyestradiol is a prodrug of 2-methoxyestradiol.

Zacharia LC, Piché CA, Fielding RM, Holland KM, Allison SD, Dubey RK, Jackson EK.

J Pharmacol Exp Ther. 2004 Jun;309(3):1093-7. Epub 2004 Feb 10.

7.

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ.

Antimicrob Agents Chemother. 2002 Mar;46(3):828-33.

8.

Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers.

Bekersky I, Fielding RM, Dressler DE, Kline S, Buell DN, Walsh TJ.

J Clin Pharmacol. 2001 Sep;41(9):963-71.

PMID:
11549101
10.

Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats.

Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ.

Pharm Res. 2000 Dec;17(12):1494-502.

PMID:
11303959
11.
12.

Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs.

Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ.

Pharm Res. 1999 Nov;16(11):1694-701.

PMID:
10571274
13.

Lipid-based amphotericin B formulations: from animals to man.

Bekersky I I, Fielding RM, Buell D, Lawrence I I.

Pharm Sci Technolo Today. 1999 Jun;2(6):230-236.

PMID:
10366838
14.
15.
16.
17.

Recombinant human hemoglobin inhibits both constitutive and cytokine-induced nitric oxide-mediated relaxation of rabbit isolated aortic rings.

Rioux F, Petitclerc E, Audet R, Drapeau G, Fielding RM, Marceau F.

J Cardiovasc Pharmacol. 1994 Aug;24(2):229-37.

PMID:
7526054
18.
19.

Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs.

Fielding RM, Singer AW, Wang LH, Babbar S, Guo LS.

Antimicrob Agents Chemother. 1992 Feb;36(2):299-307.

21.

Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective.

Fielding RM.

Clin Pharmacokinet. 1991 Sep;21(3):155-64. Review. No abstract available.

PMID:
1764868
22.
23.

The use of inhaled liposome formulations for drug delivery to the lungs and systemic circulation.

Fielding RM.

Proc West Pharmacol Soc. 1989;32:103-6. Review. No abstract available.

PMID:
2674953
24.

Time-dependent, plasma-sulfate-independent kinetics of salicylamide in dogs.

Waschek JA, Fielding RM, Tozer TN, Effeney DJ, Pond SM.

J Pharmacokinet Biopharm. 1988 Apr;16(2):151-9.

PMID:
3418492
25.

Nonlinear intestinal first-pass metabolism of salicylamide in dogs after portacaval transposition.

Pond SM, Waschek JA, Mahacha V, Fielding RM, Effeney DJ, Tozer TN.

J Pharmacol Exp Ther. 1988 Apr;245(1):291-3.

PMID:
3361447
26.

Availability of plasma sulfate for conjugation of salicylamide in dogs.

Waschek JA, Fielding RM, Tozer TN, Effeney DJ, Pond SM.

Biochem Pharmacol. 1986 Feb 1;35(3):544-6. No abstract available.

PMID:
3947388
27.

Extrahepatic extraction of salicylamide in dogs.

Fielding RM, Waschek JA, Effeney DJ, Pogany AC, Pond SM, Tozer TN.

J Pharmacol Exp Ther. 1986 Jan;236(1):97-102.

PMID:
3941404
28.

Dose-dependent sulfoconjugation of salicylamide in dogs: effect of sulfate depletion or administration.

Waschek JA, Fielding RM, Pond SM, Rubin GM, Effeney DJ, Tozer TN.

J Pharmacol Exp Ther. 1985 Aug;234(2):431-4.

PMID:
4020679
29.

Dose-dependent bioavailability and metabolism of salicylamide in dogs.

Waschek JA, Rubin GM, Tozer TN, Fielding RM, Couet WR, Effeney DJ, Pond SM.

J Pharmacol Exp Ther. 1984 Jul;230(1):89-93.

PMID:
6747835

Supplemental Content

Loading ...
Support Center